drugset / Trial / NCT07750158
Zanzalintinib Alone or in Combination With Pembrolizumab and Berahyaluronidase Alfa in Participants With Colorectal Cancer With Molecular Residual Disease
RandomizedParallel-groupTriple-blindTreatment
Summary
The primary objective of this study is to evaluate the effectiveness of zanzalintinib + Pembrolizumab (+) berahyaluronidase alfa and zanzalintinib alone compared with placebo.
Timeline
- Start
- 2026-08-25
- Primary completion
- 2030-04-05
- Completion
- 2030-04-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Berahyaluronidase alfa | Protein / enzyme biologic | — | Subcutaneous |
| Subject | Pembrolizumab | Monoclonal antibody | — | Subcutaneous |
| Subject | Zanzalintinib | Small molecule | — | Oral |